Daratumumab injection therapy for cancer may help in hard-to-treat ITP
Daratumumab, an injection therapy approved to treat myeloma, may help to control immune thrombocytopenia (ITP) in individuals whose disease doesn’t respond well to available…
News
New funding will launch trial of tAN for heavy menstrual bleeding
Spark Biomedical has been awarded funding from The Missed Vital Sign, Wellcome Leap’s $50 million program in women’s health, which it will use…
Lupus may alter iTTP symptoms, outcomes: Study
People with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who also have systemic lupus erythematosus (SLE) — have different symptoms and longer periods without disease relapse…
Ianalumab lengthens time patients can maintain safe platelet levels
A Phase 3 clinical trial testing ianalumab (VAY736) in combination with Promacta (eltrombopag) in people with primary immune thrombocytopenia (ITP) has met its main…
More Haemate-P use could mean big cost savings for Spain: Study
Increasing the use of Haemate-P to treat von Willebrand disease (VWD) could yield substantial savings for the healthcare system in Spain, a study found.
Platelet transfusion tied to much higher risk of death in TTP: Study
Platelet transfusions more than double the risk of death among people with thrombotic thrombocytopenic purpura (TTP), according to a review of published studies.
AI predicts how kids with ITP will respond to rituximab infusion
Artificial intelligence (AI) can accurately predict a response to the second-line therapy rituximab in children and adolescents with immune thrombocytopenia (ITP), according to a…
Heavy menstrual bleeding prevalent in women with VWD
About two-thirds of women with von Willebrand disease (VWD) experience heavy menstrual bleeding, according to a study from Sweden. Data also showed that…
High blood pressure may have no effect on acute TTP recovery
There appears to be no link between high blood pressure in the first two days after an acute episode of thrombotic thrombocytopenic purpura (TTP)…
Boosting platelet counts in ITP is aim of efgartigimod study
A Phase 3 trial testing efgartigimod administered into a vein in adults with primary immune thrombocytopenia (ITP) is still enrolling participants and its top-line…
